Quantumup
Oct 5, 1:27 PM
Stifel reiterated
$ALKS Buy-
$63 after hosting the Co's CEO Blair Jackson and IR Sandy Coombs on an NDR on the West Coast.
CNTA -
$LLY $TAK OTSKY AXSM SUPN
Stifel said in its note: Recall, Mr. Jackson has recently transitioned into the CEO role after serving as COO at ALKS--the focus continues to be on scaling growth at Alkermes.
Key takeaways from the meetings were:
(1) continued confidence in the upcoming Vibrance-3 ph2 readout in IH this year, where management is looking to show a clear benefit on ESS and IHSS,
(2) observation of strong enrollment in the NT1/NT2 Brilliance ph3s--where we may see topline data as early as next summer,
(3) confidence in the commercial opportunity and positioning of alixorexton, and
(4) enthusiasm around the early profile of ALKS 7290, where management highlighted the consistent response across endpoints in the ADHD ph1b.
Bottom line: after a pullback, we think the stock is attractive here ahead of various catalysts.
